Endonovo Therapeutics...
Unlike the other companies discussed in this article, Endonovo Therapeutics (OTCQB:ENDV) takes a totally different approach to creating liver disease therapies. This company focuses on developing non-implantable and non-invasive bioelectronic devices and therapies. These devices build upon Time-Varying Electromagnetic Field (TVEMF) technology originally developed at NASA that uses electromagnetic pulses to deliver electrical stimulation to the nervous system, tissues and organs to reduce inflammation and cell death.
The company's lead product, Immunotronics, makes use of a non-invasive immuno-regulatory device for preventing and treating vital organ failure through the reduction of inflammation and cell death. The technology was identified in pre-clinical studies to be a novel non-pharmacological method of treating acute inflammation. Currently, Endonovo's Immunotronics platform is geared towards targeting acute inflammation in vital organs and in particular the liver, which appears to hold the most potential in proving efficacy of the device as well as generating returns.
There are a number of reasons why Endonovo could prove to be a game changer in the liver treatment space once its bioelectronic device gets approved by the FDA as a medical device. For starters, the company won't spend as much money and time in clinical trials compared to new drugs, meaning it can be brought to market much faster.
Also, these devices could ultimately prove to be the best solution for liver disease treatments since they don't expose patients to any risk of drug induced liver injury. Conservatively, even if Endonovo's devices manage to capture just 1 percent of the total liver treatments in the U.S., the company's $50 million valuation will more than double. Furthermore, unlike other treatments for liver diseases, which target narrow physiologic and pathologic processes, Endonovo's technology broadly targets inflammation and excessive cell death, which are believed to be the principal drivers of vital organ failure.
This means if Endonovo proves its technology reduces inflammation in the liver and treat/prevent liver failure, then the possibility exists it can replicate those results in other organs like the kidneys or heart as well. As such, this would imply its current share price of under $1 doesn't reflect the massive opportunity presented by the company. Essentially, Endonovo is part of the liver disease space, although not solely a liver disease company.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
https://seekingalpha.com/article/3968546-4-st...treatments
Unlike the other companies discussed in this article, Endonovo Therapeutics (OTCQB:ENDV) takes a totally different approach to creating liver disease therapies. This company focuses on developing non-implantable and non-invasive bioelectronic devices and therapies. These devices build upon Time-Varying Electromagnetic Field (TVEMF) technology originally developed at NASA that uses electromagnetic pulses to deliver electrical stimulation to the nervous system, tissues and organs to reduce inflammation and cell death.
The company's lead product, Immunotronics, makes use of a non-invasive immuno-regulatory device for preventing and treating vital organ failure through the reduction of inflammation and cell death. The technology was identified in pre-clinical studies to be a novel non-pharmacological method of treating acute inflammation. Currently, Endonovo's Immunotronics platform is geared towards targeting acute inflammation in vital organs and in particular the liver, which appears to hold the most potential in proving efficacy of the device as well as generating returns.
There are a number of reasons why Endonovo could prove to be a game changer in the liver treatment space once its bioelectronic device gets approved by the FDA as a medical device. For starters, the company won't spend as much money and time in clinical trials compared to new drugs, meaning it can be brought to market much faster.
Also, these devices could ultimately prove to be the best solution for liver disease treatments since they don't expose patients to any risk of drug induced liver injury. Conservatively, even if Endonovo's devices manage to capture just 1 percent of the total liver treatments in the U.S., the company's $50 million valuation will more than double. Furthermore, unlike other treatments for liver diseases, which target narrow physiologic and pathologic processes, Endonovo's technology broadly targets inflammation and excessive cell death, which are believed to be the principal drivers of vital organ failure.
This means if Endonovo proves its technology reduces inflammation in the liver and treat/prevent liver failure, then the possibility exists it can replicate those results in other organs like the kidneys or heart as well. As such, this would imply its current share price of under $1 doesn't reflect the massive opportunity presented by the company. Essentially, Endonovo is part of the liver disease space, although not solely a liver disease company.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
https://seekingalpha.com/article/3968546-4-st...treatments
